Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATXI Nasdaq 2834 http://www.avenuetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avenue Therapeutics Inc

ATXI: InvaGen Acquisition Spices Up Quarterly Report - Dec 3rd, 2018 7:15 am
Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement - Nov 21st, 2018 5:45 am
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights - Nov 14th, 2018 2:30 pm
ATXI: InvaGen Capital Raise & Acquisition - Nov 13th, 2018 10:00 am
InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S. - Nov 13th, 2018 4:30 am
ATXI: Second Quarter 2018 Results - Aug 27th, 2018 11:45 am
Special Report: Biotech incubator taps investors through in-house brokerage - Aug 2nd, 2018 8:29 am
ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol - Jun 12th, 2018 7:30 am
Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol - May 23rd, 2018 5:25 am
Benzinga Pro's 5 Stocks To Watch Today - May 21st, 2018 6:59 am
ATXI: 1Q:18 Update Confirms Timeline - May 14th, 2018 8:30 am
ATXI: No Pain? We See a Gain; Developing Tramadol - Apr 10th, 2018 11:20 am